• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Acetylcholinesterase inhibitors may lower risk of AMD in patients with Alzheimer disease

News
Article

The data indicated that patients with Alzheimer’s disease who were treated with acetylcholinesterase inhibitors had a slightly lower hazard of developing AMD compared with untreated patients.

neurologist looks at brain scans of patient with Alzheimers, which may coincide with AMD - Image credit: Atthapon—stock.adobe.com

(Image credit: Atthapon—stock.adobe.com)

Patients taking acetylcholinesterase inhibitors for Alzheimer’s disease may have a reduction in the risk of developing age-related macular degeneration (AMD),1 according to first author S. Scott Sutton, PharmD, from the Dorn Research Institute, Columbia VA Health Care System, Columbia, and Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia.

He and his colleagues acted on the hypothesis that AMD results partly from inflammatory reactions in the macula. Because acetylcholinesterase inhibitors have anti-inflammatory effects, they wanted to determine if these drugs reduce the risk of AMD in patients with Alzheimer’s disease.

To do so, they investigated the association between acetylcholinesterase inhibitors and the incidence of AMD in a propensity score–matched retrospective cohort study. Patients who were in health care facilities in the US Department of Veterans Affairs (VA) health care system were included from January 2000 through September 2023. All participants were aged 55 to 80 years and received a diagnosis of Alzheimer’s disease during those ages; in addition, none had a preexisting diagnosis of AMD in the VA database.

All included patients had been treated with acetylcholinesterase inhibitors for Alzheimer’s disease. The study’s main outcome measure was the first diagnosis of AMD.

Data analysis for AMD

The investigators reported that 21,823 veterans with Alzheimer’s disease were identified and included in the study.The mean patient age was 72.3 years. The vast majority, 97.7% were men.

The analysis showed that “Propensity score–matched Cox model reveals each additional year of acetylcholinesterase inhibitors treatment was associated with a 6% lower hazard of AMD (hazard ratio, 0.94; 95% confidence interval, 0.89-0.99),” the authors reported.

The data indicated that patients with Alzheimer’s disease who were treated with acetylcholinesterase inhibitors had a slightly lower hazard of developing AMD compared with untreated patients. In contrast, the use of memantine, another treatment for Alzheimer’s disease, was not found to be associated with the incidence of AMD in this study.

The investigators concluded, “This observational study reports a small reduction in the risk of AMD among veterans with Alzheimer’s disease receiving acetylcholinesterase inhibitors. Randomized clinical trials would be needed to determine if there is a cause-and-effect relationship and further research is required to validate these findings across diverse populations.”

Reference
1. Sutton SS, Magagnoli J, Cummings TH, et al. Alzheimer disease treatment with acetylcholinesterase inhibitors and incident age-related macular degeneration. JAMA Ophthalmol. Published online January 4, 2024. doi:10.1001/jamaophthalmol.2023.6014
Related Videos
Andy Morgenstern, OD, FAAO, FNAP chats with Optometry Times
R Tracy Williams, OD, FAAO with Optometry Times
Shan Lin, MD, speaks on Glaucoma 360 presentation in an interview with Ophthalmology Times
Cecelia Koetting, OD, FAAO, DIPABO, left, speaks with Optometry Times about the 2024 EnVision Summit
Bonnie An Henderson, MD, highlights key takeaways of the 2024 EnVision Summit, including diversity and family inclusion
Danica Marrelli, OD, FAAO, AAO Dipl, co-chair of EnVision Summit chats about geographic atrophy and glaucoma panels
© 2024 MJH Life Sciences

All rights reserved.